Methodology
How the edition was made: methods, the model card, the evidence cut and its age, the acceptance record and the glossary.
విషయసూచిక
- ·Edition home
- ·Executive summary
- 1Synthetic biology is a build capability and a governance test
- 2Key findings
- 3Systems and sectors at baseline
- 4Risks and capability
- 5Design capability outpaces screening and oversight
- 6Readings from the other desks
- 7The 2027 agenda
- 8Systems in depth
- AMethodology
- A.1 Methods
- A.2 Model card, Synthetic biology System Model v0
- A.3 The baseline evidence cut
- A.4 Evidence age and coverage
- A.5 Evidence cards, two anchor sources
- A.6 Publication acceptance record
- A.7 Status words
- A.8 How the edition is made, released and corrected
- A.9 Glossary and abbreviations
- A.10 Technical annex
- BData appendix
- CReferences and record
- ·Complete edition, for print
A.1పద్ధతులు
The global baseline uses published values and four simple derivations. Each is shown in full so that any reader can reproduce it.
| No. | Derivation | Calculation | ఫలితం |
|---|---|---|---|
| (1) | Fall in codons from the standard code to Syn57 | 64 minus 57 | 7 codons |
| (2) | Growth in recoded codons, Syn57 against Syn61 (lower bound) | 101,000 ÷ 18,214 | about 5.5 times |
| (3) | Change in Ginkgo Bioworks revenue, 2024 to 2025 | (170.155 minus 227.043) ÷ 227.043 | about minus 25% |
| (4) | Share of Twist Bioscience third-quarter revenue from DNA synthesis and protein solutions | 56.6 ÷ 118.4 | about 48% |
| Strength | Definition |
|---|---|
| STRONG | a disruption in the source system has historically changed the target system’s service or output within one season, in more than one region |
| MODERATE | an effect is documented but buffered or slower |
| WEAK | an effect is plausible but not documented at global scale |
| లేబుల్ | Rule |
|---|---|
| నివేదించబడింది | value as issued by its source, with year |
| Inferred | reasoned from cited evidence; never a measurement |
| అంచనా | Nexus analytical value with stated method |
| దృశ్యం | conditional on stated assumptions |
| Expert input | structured editorial judgement awaiting evidence |
A.2Model card, Synthetic biology System Model v0
- Model ID
- MDL-XT04-SYNBIO · v0.1
- Purpose
- represent synthetic biology as a build capability and manufacturing base coupled to health, food, energy, feedstock, finance, workforce and biosecurity
- Family
- graph-based system of systems
- Inputs
- the cited sources of this edition; no proprietary data
- పద్ధతి
- expert-specified coupling strengths (STRONG · MODERATE · WEAK) from assessments and analogue events
- ధ్రువీకరణ
- none yet, first validation against federation evidence in 2027
- అనిశ్చితి
- qualitative; strengths are hypotheses, not measurements
- Domain of validity
- global scale; not for asset-, site- or country-level use
- Reproducibility
- strength table and sources published in this edition
typed in v0
documented within one season
documented, buffered
plausible, undocumented
A.3The baseline evidence cut
Every Nexus edition is published from a frozen evidence cut. The global baseline cut is documentary: it pins the exact edition of every source cited. Federation cuts begin with the first national Foundry cuts in 2027.
- Cut ID
- DC-XTECH-SYNBIO-GLOBAL-2026-B0
- రకం
- baseline documentary cut
- Resolution policy
- pinned · as of 30 September 2026
- Sources pinned
- 44 cited sources, each at the edition and access date in the references
- Model runs
- none at baseline, analytical values are stated with their method
- Digest
- computed at freeze and recorded in the publication record
- Supersedes
- nothing, first cut of the series
- Superseded by
- the 2027 synthetic biology annual cut
వంశావళి
- 01
source edition
- 02
pinned citation
- 03
finding
- 04
page
- 05
publication record
| Element | Baseline 2026 | 2027 global annual |
|---|---|---|
| మూలాలు | cited global publications, pinned by edition | national, regional and sector cuts through one graph |
| Analysis | stated methods and editorial estimates | typed analysis specifications |
| Models | Synthetic biology System Model v0 specification | model runs with receipts |
| Findings | twelve baseline findings | findings re-bound to federation evidence |
| సమీక్ష | five passes scheduled | five passes on the exact digest |
A.4Evidence age and coverage
A 2026 global edition rests on evidence observed in many different years. This page shows each time base, so that no single year label hides older evidence.
| Indicator | పరిశీలించినది | Released | Cadence | Next release |
|---|---|---|---|---|
| Recoded genome results | 2019 to 2025 | Nature 2019 · Science Oct 2025 | one-off | follow-up papers |
| Synthetic yeast | 2023 | Cell Dec 2023 | one-off | completion papers |
| Screening study | 2025 | Science Oct 2025 | one-off | follow-up studies |
| US commission report | 2025 | Apr 2025 | one-off | legislation |
| US screening framework | 2024 · 2025 order | Apr 2024 · May 2025 | periodic | replacement text |
| EU Biotech Act | 2025 | Dec 2025 | periodic | second act |
| OECD governance paper | 2026 | May 2026 | one-off | next policy paper |
| Company results | 2025 to 2026 | Feb 2026 · Aug 2026 | quarterly | next earnings |
| వ్యవస్థ | కవరేజ్ | Thinnest dimension |
|---|---|---|
| Build capability | GOOD | industrial-scale performance |
| Clinical | PARTIAL | long-term outcomes |
| Biosecurity | PARTIAL | screening coverage |
| పాలన | PARTIAL | text of replacement US framework |
| Investment | THIN | common basis for public and private |
| Energy and feedstock | THIN | fermentation footprint |
| సామర్థ్యం | THIN | biofoundry and plant counts |
| Skills | THIN | workforce numbers |
| క్షేత్రం | Source that would fill it | Blocker |
|---|---|---|
| Energy, water and feedstock use of biomanufacturing at scale | producers, national laboratories, peer-reviewed life-cycle studies | not retrieved on a common basis; no study opened |
| DNA synthesis capacity and screening coverage by provider and country | providers, industry consortia, national agencies | no consolidated series found; screening pages not opened |
| Status and text of the US screening framework after the 2025 order | OSTP and White House publications2526 | framework and order read; no replacement text published; CRS reported in September 2026 that the 2024 framework had not been updated27 |
| European Commission text of the Biotech Act proposal | European Commission proposal COM(2025) 102228 | proposal text read from a national parliament copy; detail beyond the chapters cited not reviewed22 |
| Status of the EU second Biotech Act | European Commission, European Parliament legislative train29 | announced only; the legislative train edition of 20 September 2026 gives a Q3 2026 indicative date and no proposal |
| Public and private investment in synthetic biology on one basis | national statistics, OECD, industry surveys | not retrieved; only two company filings used1617 |
| Biofoundry and fermentation capacity by country | industry and trade statistics | not retrieved |
| Programme totals for the US distributed bioindustrial manufacturing awards after September 2024 | US manufacturing programme pages24 | the page read lists totals to September 2024 only |
| Bioeconomy size from a primary statistical source | national accounts, OECD | only a secondary commentary figure read15 |
| Workforce size and skills gaps | national statistics, OECD, industry surveys | not retrieved; capability rung stays LISTED |
| Independent replication and viral-resistance tests of recoded strains | peer-reviewed papers | not found at evidence close |
| Long-term outcomes of engineered therapies | trial follow-up publications | only the cited trial and one case report read810 |
| Mirror life risk assessment beyond the policy forum | peer-reviewed risk studies | only the forum abstract read12 |
| Capability rungs beyond guidance and planning | agencies, operators, laboratories | not reviewed |
A.5Evidence cards, two anchor sources
Published in Science 390 (2025) by Robertson and colleagues; news page of 1 August 2025. One-off. Role: binds BLD-001. Coverage: one organism in one laboratory line.
EVD-XT04-001
Escherichia coli with a 57-codon genetic code1
Published in Science 390 (2025). One-off study. Role: binds SEC-005. Coverage: screening tools and open design software; no sequence detail is reproduced here.
EVD-XT04-002
Strengthening nucleic acid biosecurity screening against generative protein design tools13
| Dimension | EVD-XT04-001 | EVD-XT04-002 |
|---|---|---|
| Completeness | one organism; about 4 million base pairs | a set of screening tools and design software |
| Timeliness | news page about 12 weeks before the journal date | journal publication in 2025 |
| Revision | preprint and journal versions | patches reported after testing |
| Method transparency | methods published in the paper | details limited for security reasons |
| External validation | peer review | peer review |
Evidence cards to follow in 2027
A.6Publication acceptance record
Editorial self-check at evidence close. Every applicable item carries a disposition; the remaining items are review, approval and deposit.
| సమూహం | ప్రాంతం | Items | Pass | N/A | Pending |
|---|---|---|---|---|---|
| D1 | Identity and scope | 8 | 8 | 0 | 0 |
| D2 | Source and data | 12 | 9 | 1 | 2 |
| D3 | Analysis and models | 12 | 3 | 8 | 1 |
| D4 | Findings and claims | 9 | 8 | 0 | 1 |
| D5 | Figures, tables, maps | 10 | 6 | 2 | 2 |
| D6 | Editorial and citations | 10 | 8 | 0 | 2 |
| D7 | Review and approval | 13 | 0 | 0 | 13 |
| D8 | Artefact and design | 12 | 7 | 0 | 5 |
| D9 | Registry and release | 9 | 0 | 0 | 9 |
Publication gate
- Conditions met
- 14 of 23 at evidence close
- Blocking problems
- none recorded
- Open conditions
- reviews, approval of the exact digest, deposit, registry pointer
Not applicable at baseline
- Model runs
- first runs in Q1 2027
- మ్యాప్లు
- plates in Q2 2027
- Waivers
- none
A.7Status words
| స్థితి | దీని అర్థం ఏమిటి |
|---|---|
| పరిశీలించినది | Measured directly and published by the source. |
| నివేదించబడింది | Published statistics of an official or institutional source. |
| Declared | Stated by the body concerned; not independently measured. |
| అంచనా | A Nexus estimate from cited evidence, with its method in Annex A. |
| నమూనా ఆధారితం | Produced by a stated model from cited inputs. |
| Inferred | Reasoned from cited evidence; not measured. |
| Forecast | A projection by the cited source. |
| Simulated | A simulation result under stated assumptions. |
| దృశ్యం | A conditional statement under stated assumptions; never a prediction. |
| Expert input | Expert judgement, recorded with its basis. |
| Candidate | Proposed for a later edition; not yet evidence. |
| Evidence-quality levels (EQL 1 to 5) grade the source behind a value; they are not a score of the subject. | |
A.8How the edition is made, released and corrected
Every edition is built from a sealed evidence cut, reviewed under three keys, signed and deposited before any site shows it as published; corrections go to Nexus Standards as change proposals and feed the next cut.
| దశ | What happens | మూలం |
|---|---|---|
| 01 Evidence arrives from the pillars | Foundry seals observations and indicator series, Universe hands over after-action and scenario findings, and contributions are screened at every gateway, including this site’s. | |
| 02 The cut is sealed | On the cut date the evidence is pinned under one identifier, so anyone can rebuild the edition from exactly what it was built on. | |
| 03 The edition is assembled | The edition is drafted from its template and content pack. Agents may draft; they never publish and never decide. | |
| 04 The keys turn | At the publisher of record the truth key comes first: every value is checked against its source or stated method before the meaning and capital keys turn. No edition moves on until every key has been turned by a named steward. | |
| 05 The gate opens | A named approver releases one exact digest of the edition; any change after this point is a new version, never a silent edit. | |
| 06 Signed and deposited | The PDF, the web edition and the data bundle are signed together with a manifest and an RO-Crate description, and deposited on Zenodo with a concept and a version DOI. | |
| 07 Published on its desk’s site | Only then does the edition show as published on its desk’s Reports site, and the Collection lists it as a part. | |
| 08 Corrections go to Standards | Method and correction findings go to Nexus Standards as change proposals; citations, corrections and new contributions feed the next evidence cut. |
A teaching model of the process, not a forecast and not a record of any run; dates and counts on this page come from the programme record. Sources: Reports governance at GCRI Canada (2026); Zenodo, repository of record for Reports deposits (2026).
Lifecycle, one state at a time: Draft, Computed, Evidence bound, Reviewed, Approved for release, Published, Corrected, Superseded. This edition is a draft.
A.9Glossary and abbreviations
| Term | Meaning |
|---|---|
| Baseline Edition | the inaugural annual edition that fixes the reference state for the series |
| WEFH+B | water, energy, food, health and biodiversity, the national nexus core |
| అనుసంధానం | a typed dependency through which one system transmits to another |
| Protection gap | the share of losses not covered by insurance |
| Capability ladder | LISTED → EXISTS → ADEQUATE → TESTED → DEMONSTRATED |
| EQL | evidence-quality level, 1–5 |
| Evidence cut | a frozen resolution of exact sources and versions |
| NNC · NLC · NWG | National Nexus Consortium · National Leadership Council · National Working Groups |
| Abbreviation | Expansion |
|---|---|
| AHTEG | Ad Hoc Technical Expert Group |
| BWC | Biological Weapons Convention |
| CBD | జీవ వైవిధ్యంపై ఒప్పందం |
| CRS | Congressional Research Service |
| DBIMP | Distributed Bioindustrial Manufacturing Program |
| EO | executive order |
| FDA | US Food and Drug Administration |
| IGSC | International Gene Synthesis Consortium |
| NSCEB | National Security Commission on Emerging Biotechnology |
| OECD | Organisation for Economic Co-operation and Development |
| OSTP | Office of Science and Technology Policy |
| SPC | supplementary protection certificate |
A.10Technical annex
| Item | Annex | విషయసూచిక | స్థితి |
|---|---|---|---|
| A.1 | Indicator definitions | the global indicator set, with units and sources | IN THIS EDITION |
| A.2 | Coupling strengths | the twenty-cell matrix and its rationale | IN THIS EDITION |
| A.3 | Scenario specification | SCN-XT04-DSG-01 assumptions and signposts | IN THIS EDITION |
| A.4 | Capability placements | rung evidence for fifteen functions | IN THIS EDITION |
| A.5 | Model diagnostics | first runs and validation | 2027 |
| A.6 | Sensitivity analyses | influence of coupling strengths | 2027 |
| A.7 | Cluster notes | cards for the major platform, DNA supply and manufacturing clusters | 2027 |
| A.8 | Review statements | pass-by-pass review record | AT RELEASE |
A.1 · indicator definition: codons recoded
- Construct
- number of codon positions in a genome replaced by a synonymous codon
- Unit
- count of codons
- పద్ధతి
- genome design, fragment synthesis and assembly
- మూలం
- Nature 569 (2019)3; Science 390 (2025) and the research institute news page2
- అనిశ్చితి
- the Syn57 count is stated as over 101,000, a lower bound
- Known limits
- counts may include sense codons and a stop codon; one lineage of organisms
Notes
Numbers are the edition’s reference numbers, so a note reads the same in every chapter. The full list, with every source and its licence, is in Annex C. Annex C, references
- 25National Science and Technology Council, Fast Track Action Committee on Synthetic Nucleic Acid Procurement Screening (ed.), Framework for Nucleic Acid Synthesis Screening (version 1 April 2024, revised September 2024; framework document read). Office of Science and Technology Policy, Washington. Observation year 2024. Accessed 2026-11-05.back
- 26The White House (ed.), Executive Order 14292 of 5 May 2025, Improving the Safety and Security of Biological Research, Federal Register 2025-08266, 8 May 2025 (text read; section 4(b) gives OSTP 90 days to revise or replace the 2024 Framework for Nucleic Acid Synthesis Screening). Office of the Federal Register, Washington. Observation year 2025. Accessed 2026-11-05.back
- 27Congressional Research Service (ed.), Artificial Intelligence and Biosecurity Issues, CRS In Focus IF13269, 16 July 2026, updated 3 August and 15 September 2026 (all three versions read; the July version states that CRS could not determine whether the 2024 policy and the 2024 screening framework had been revised or replaced; the September update states that a July 2026 policy replaced the 2024 dual-use research policy and that OSTP had not updated the 2024 screening framework). Library of Congress, Washington. Observation year 2026. Accessed 2026-11-05.back
- 28European Commission (ed.), Proposal for a Regulation on establishing a framework of measures for strengthening Union’s biotechnology and biomanufacturing sectors particularly in the area of health (European Biotech Act), COM(2025) 1022 final, 2025/0406 (COD), Strasbourg, 16 December 2025 (proposal text read from the copy transmitted to the Austrian Parliament; health biotechnology investment pilot with the European Investment Bank Group; 12-month extension of the supplementary protection certificate; chapter on biodefence and preventing biotechnology misuse). European Commission, Brussels. Observation year 2025. Accessed 2026-11-05.back
- 22Baker McKenzie (ed.), EU Biotech Act unveiled: Commission proposal to turn Europe into a biotech powerhouse (law firm summary, 19 December 2025; proposal of 16 December 2025; health focus; investment pilot with the European Investment Bank Group; 12-month certificate extension; biodefence measures; second act expected in Q3 2026). Secondary source, not the Commission text. Observation year 2025. Accessed 2026-11-03.back
- 29European Parliament (ed.), Legislative Train Schedule: European Biotech Act II (edition of 20 September 2026 read; status announced; Commission work programme 2026 indicative date Q3 2026; would broaden the health-focused Act I to industrial biotechnology and biomanufacturing). European Parliament, Brussels. Observation year 2026. Accessed 2026-11-05.back
- 16Twist Bioscience Corporation (ed.), Form 8-K exhibit 99.1, results for the fiscal third quarter ended 30 June 2026 (company filing; revenue USD 118.4 million; nine months USD 332.8 million; fiscal 2026 guidance USD 456 to 457 million; company statements and guidance are weak evidence). US Securities and Exchange Commission, Washington. Observation year 2026. Accessed 2026-11-03.back
- 17Ginkgo Bioworks Holdings, Inc. (ed.), Form 8-K exhibit 99.1, fourth quarter and full year 2025 results (company filing of 26 February 2026; revenue USD 170.155 million against USD 227.043 million; net loss USD 312.763 million; company statements are weak evidence). US Securities and Exchange Commission, Washington. Observation year 2025. Accessed 2026-11-03.back
- 24US Manufacturing Program (ed.), Bioindustrial (programme topic page; Distributed Bioindustrial Manufacturing Program awards announced 10 July to 13 September 2024; 25 awards; USD 42 million cumulative). Manufacturing USA, Gaithersburg. Observation year 2024. Accessed 2026-11-03.back
- 15Federation of American Scientists (ed.), Translating Vision into Action: FAS commentary on the NSCEB final report (commentary page; six pillars; cites over USD 210 billion of US GDP and over 640,000 jobs for the bioeconomy; secondary and advocacy-leaning source). Federation of American Scientists, Washington. Observation year 2025. Accessed 2026-11-03.back
- 8Frangoul, H. et al., Exagamglogene autotemcel for severe sickle cell disease, New England Journal of Medicine 390 (18), 1649 to 1662, 2024 (record read via Europe PMC: 44 treated; 29 of 30 evaluable free of severe crises for 12 months; median follow-up 19.3 months). Massachusetts Medical Society, Waltham. Observation year 2024. Accessed 2026-11-03.back
- 10Musunuru, K. et al., Patient-specific in vivo gene editing to treat a rare genetic disease, New England Journal of Medicine 392 (22), 2235 to 2243, 2025 (record read via Europe PMC: one infant; two infusions at about 7 and 8 months). Massachusetts Medical Society, Waltham. Observation year 2025. Accessed 2026-11-03.back
- 12Confronting risks of mirror life, Science 386, 1351 to 1353, 2024 (record read via Europe PMC; the record gives only a one-line abstract calling for broad discussion). American Association for the Advancement of Science, Washington. Observation year 2024. Accessed 2026-11-03.back
- 1Robertson, W.E. et al., Escherichia coli with a 57-codon genetic code, Science 390 (6771), eady4368, published 23 October 2025 (record read via PubMed, PMID 40743368; the record gives a 4 megabase synthetic genome and six replaced sense codons). American Association for the Advancement of Science, Washington. Observation year 2025. Accessed 2026-11-03.back
- 13Strengthening nucleic acid biosecurity screening against generative protein design tools, Science 390 (6768), 82 to 87, 2025 (record read via Europe PMC; abstract only; no method detail used). American Association for the Advancement of Science, Washington. Observation year 2025. Accessed 2026-11-03.back
- 3Fredens, J. et al., Total synthesis of Escherichia coli with a recoded genome, Nature 569 (7757), 514 to 518, 2019 (record read via Europe PMC: 18,214 codons recoded; 61-codon genome). Springer Nature, London. Observation year 2019. Accessed 2026-11-03.back
- 2MRC Laboratory of Molecular Biology (ed.), Syn57 represents a new chapter in the genetic code of life (news page, 1 August 2025; over 101,000 codons recoded; 64 to 57 codons; genome of about 4 megabases built from 38 fragments of about 100 kilobases). MRC Laboratory of Molecular Biology, Cambridge. Observation year 2025. Accessed 2026-11-03.back